Skip to main content
Monday, November 16, 2026Nov 16

Belgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs

FILE - The North American headquarters of Belgian pharmaceutical company UCB is seen, Nov. 10, 2014, in Smyrna, Ga. (Paul Abell/AP Images for UCB, Inc., File)
FILE - The North American headquarters of Belgian pharmaceutical company UCB is seen, Nov. 10, 2014, in Smyrna, Ga. (Paul Abell/AP Images for UCB, Inc., File)

ATLANTA (AP) — Belgian pharmaceutical company UCB announced Tuesday that it would invest $2 billion to build a drug-making plant in suburban Atlanta.

The rapidly growing drugmaker said the plant, which would employ about 330 people upon completion, would anchor its effort to sell more drugs in the United States.

“This decision reflects our confidence in UCB’s long-term growth and our deep-rooted commitment to the United States,” company CEO Jean-Christophe Tellier said in a statement.

UCB had announced in June that it wanted to build a new U.S. factory, as well as hire more U.S.-based contract manufacturers to make drugs. The company already has about 2,000 U.S. employees. The company has been growing rapidly, seeing revenues grow 26% to nearly $9 billion (7.74 billion euros) in 2025. Profit jumped even more, up 46% to $1.81 billion (1.56 billion euros.)

“The new biologics facility in Gwinnett County, Georgia, is designed to meet increasing demand and ensure patients receive reliable, timely access to vital treatments,” UCB executive Jacques Marbehant wrote in a blog post.